Priyamvada Gupta1, Rakesh Jalali2. 1. Neuro Oncology Group, Tata Memorial Centre, Tata Memorial Hospital, Dr Ernest Borges Road, Parel, Mumbai, 400 012, India. 2. Neuro Oncology Group, Tata Memorial Centre, Tata Memorial Hospital, Dr Ernest Borges Road, Parel, Mumbai, 400 012, India. rjalali@tmc.gov.in.
Abstract
PURPOSE OF REVIEW: We review and summarize the key issues affecting general health and quality of life (QOL) of pediatric long-term survivors of brain tumors. RECENT FINDINGS: Long-term survivors of brain tumors are at risk of considerable late morbidity and mortality. Lengthening survival in brain tumors has highlighted the deep impact of tumor and its treatment on the physical, psychological, functional, and social health and QOL of these survivors. Evolution in tumor therapy including surgery, radiotherapy, and systemic therapies, etc., has the potential to mitigate this impact to some extent. Sensitization of health staff, policy makers, and the primary designers of clinical trials towards integration of QOL end points while measuring survival in brain tumor patients is the need of the hour. New developments in tumor therapeutics must not only provide quantitative gain but also improve the quality of survival in these long-term survivors. While majority of the issues presented pertain to survivorship in pediatric brain tumor population, similar challenges are likely to exist in young adults surviving brain tumors as well.
PURPOSE OF REVIEW: We review and summarize the key issues affecting general health and quality of life (QOL) of pediatric long-term survivors of brain tumors. RECENT FINDINGS: Long-term survivors of brain tumors are at risk of considerable late morbidity and mortality. Lengthening survival in brain tumors has highlighted the deep impact of tumor and its treatment on the physical, psychological, functional, and social health and QOL of these survivors. Evolution in tumor therapy including surgery, radiotherapy, and systemic therapies, etc., has the potential to mitigate this impact to some extent. Sensitization of health staff, policy makers, and the primary designers of clinical trials towards integration of QOL end points while measuring survival in brain tumorpatients is the need of the hour. New developments in tumor therapeutics must not only provide quantitative gain but also improve the quality of survival in these long-term survivors. While majority of the issues presented pertain to survivorship in pediatric brain tumor population, similar challenges are likely to exist in young adults surviving brain tumors as well.
Entities:
Keywords:
Brain tumors; Cancer survivors; Childhood brain tumors; Long-term survivors
Authors: Nils H Ulrich; Jan-Karl Burkhardt; Carlo Serra; René-Ludwig Bernays; Oliver Bozinov Journal: Childs Nerv Syst Date: 2011-09-17 Impact factor: 1.475
Authors: Wassim Chemaitilly; Zhenghong Li; Sujuan Huang; Kirsten K Ness; Karen L Clark; Daniel M Green; Nicole Barnes; Gregory T Armstrong; Matthew J Krasin; Deo Kumar Srivastava; Ching-Hon Pui; Thomas E Merchant; Larry E Kun; Amar Gajjar; Melissa M Hudson; Leslie L Robison; Charles A Sklar Journal: J Clin Oncol Date: 2015-01-05 Impact factor: 44.544
Authors: Tara M Brinkman; Johnnie K Bass; Zhenghong Li; Kirsten K Ness; Amar Gajjar; Alberto S Pappo; Gregory T Armstrong; Thomas E Merchant; Deo Kumar Srivastava; Leslie L Robison; Melissa M Hudson; James G Gurney Journal: Cancer Date: 2015-08-19 Impact factor: 6.860
Authors: Dietmar Krex; Barbara Klink; Christian Hartmann; Andreas von Deimling; Torsten Pietsch; Matthias Simon; Michael Sabel; Joachim P Steinbach; Oliver Heese; Guido Reifenberger; Michael Weller; Gabriele Schackert Journal: Brain Date: 2007-09-04 Impact factor: 13.501
Authors: Jenny W Y Pang; Debra L Friedman; John A Whitton; Marilyn Stovall; Ann C Mertens; Leslie L Robison; Noel S Weiss Journal: Pediatr Blood Cancer Date: 2008-01 Impact factor: 3.838
Authors: Melissa M Hudson; Ann C Mertens; Yutaka Yasui; Wendy Hobbie; Hegang Chen; James G Gurney; Mark Yeazel; Christopher J Recklitis; Neyssa Marina; Leslie R Robison; Kevin C Oeffinger Journal: JAMA Date: 2003-09-24 Impact factor: 157.335
Authors: Eric W Prince; Ros Whelan; David M Mirsky; Nicholas Stence; Susan Staulcup; Paul Klimo; Richard C E Anderson; Toba N Niazi; Gerald Grant; Mark Souweidane; James M Johnston; Eric M Jackson; David D Limbrick; Amy Smith; Annie Drapeau; Joshua J Chern; Lindsay Kilburn; Kevin Ginn; Robert Naftel; Roy Dudley; Elizabeth Tyler-Kabara; George Jallo; Michael H Handler; Kenneth Jones; Andrew M Donson; Nicholas K Foreman; Todd C Hankinson Journal: Sci Rep Date: 2020-10-09 Impact factor: 4.379
Authors: Yoshiaki Sato; Noriko Shinjyo; Machiko Sato; Marie K L Nilsson; Kazuhiro Osato; Changlian Zhu; Marcela Pekna; Hans G Kuhn; Klas Blomgren Journal: Front Neurol Date: 2018-09-11 Impact factor: 4.003